Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.

Sanderson SD, Thoman ML, Kis K, Virts EL, Herrera EB, Widmann S, Sepulveda H, Phillips JA.

PLoS One. 2012;7(7):e40303. doi: 10.1371/journal.pone.0040303. Epub 2012 Jul 6.

2.

An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection.

Hung CY, Hurtgen BJ, Bellecourt M, Sanderson SD, Morgan EL, Cole GT.

Vaccine. 2012 Jun 29;30(31):4681-90. doi: 10.1016/j.vaccine.2012.04.084. Epub 2012 May 8.

3.

FimH, a TLR4 ligand, induces innate antiviral responses in the lung leading to protection against lethal influenza infection in mice.

Abdul-Careem MF, Firoz Mian M, Gillgrass AE, Chenoweth MJ, Barra NG, Chan T, Al-Garawi AA, Chew MV, Yue G, van Roojen N, Xing Z, Ashkar AA.

Antiviral Res. 2011 Nov;92(2):346-55. doi: 10.1016/j.antiviral.2011.09.004. Epub 2011 Sep 14.

PMID:
21945041
4.

Impaired immune responses in the lungs of aged mice following influenza infection.

Toapanta FR, Ross TM.

Respir Res. 2009 Nov 18;10:112. doi: 10.1186/1465-9921-10-112.

5.

Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide.

Sheen TR, Cavaco CK, Ebrahimi CM, Thoman ML, Sanderson SD, Morgan EL, Doran KS.

Vaccine. 2011 Dec 9;30(1):9-13. doi: 10.1016/j.vaccine.2011.10.054. Epub 2011 Oct 30.

6.

Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.

Karuturi BV, Tallapaka SB, Phillips JA, Sanderson SD, Vetro JA.

Clin Immunol. 2015 Dec;161(2):251-9. doi: 10.1016/j.clim.2015.06.006. Epub 2015 Jun 23.

7.

Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.

Morgan EL, Morgan BN, Stein EA, Vitrs EL, Thoman ML, Sanderson SD, Phillips JA.

Vaccine. 2009 Dec 11;28(2):463-9. doi: 10.1016/j.vaccine.2009.10.029. Epub 2009 Oct 15.

8.

Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.

Norton EB, Clements JD, Voss TG, Cárdenas-Freytag L.

J Virol. 2010 Mar;84(6):2983-95. doi: 10.1128/JVI.01805-09. Epub 2010 Jan 6.

9.

Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice.

Abe T, Takahashi H, Hamazaki H, Miyano-Kurosaki N, Matsuura Y, Takaku H.

J Immunol. 2003 Aug 1;171(3):1133-9.

10.

17╬▓-estradiol protects females against influenza by recruiting neutrophils and increasing virus-specific CD8 T cell responses in the lungs.

Robinson DP, Hall OJ, Nilles TL, Bream JH, Klein SL.

J Virol. 2014 May;88(9):4711-20. doi: 10.1128/JVI.02081-13. Epub 2014 Feb 12.

11.

Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.

Kollessery G, Nordgren TM, Mittal AK, Joshi SS, Sanderson SD.

Vaccine. 2011 Aug 11;29(35):5904-10. doi: 10.1016/j.vaccine.2011.06.070. Epub 2011 Jul 1.

PMID:
21723901
12.

Developmental exposure to bisphenol A modulates innate but not adaptive immune responses to influenza A virus infection.

Roy A, Bauer SM, Lawrence BP.

PLoS One. 2012;7(6):e38448. doi: 10.1371/journal.pone.0038448. Epub 2012 Jun 4.

13.

Protection of innate immunity by C5aR antagonist in septic mice.

Huber-Lang MS, Riedeman NC, Sarma JV, Younkin EM, McGuire SR, Laudes IJ, Lu KT, Guo RF, Neff TA, Padgaonkar VA, Lambris JD, Spruce L, Mastellos D, Zetoune FS, Ward PA.

FASEB J. 2002 Oct;16(12):1567-74.

PMID:
12374779
14.

Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic.

Tai W, Roberts L, Seryshev A, Gubatan JM, Bland CS, Zabriskie R, Kulkarni S, Soong L, Mbawuike I, Gilbert B, Kheradmand F, Corry DB.

Mucosal Immunol. 2011 Mar;4(2):197-207. doi: 10.1038/mi.2010.50. Epub 2010 Aug 25.

PMID:
20736998
15.

Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys.

Sun S, Zhao G, Liu C, Fan W, Zhou X, Zeng L, Guo Y, Kou Z, Yu H, Li J, Wang R, Li Y, Schneider C, Habel M, Riedemann NC, Du L, Jiang S, Guo R, Zhou Y.

Clin Infect Dis. 2015 Feb 15;60(4):586-95. doi: 10.1093/cid/ciu887. Epub 2014 Nov 27.

PMID:
25433014
16.

A novel adjuvant for vaccine development in the aged.

Morgan EL, Thoman ML, Sanderson SD, Phillips JA.

Vaccine. 2010 Dec 6;28(52):8275-9. doi: 10.1016/j.vaccine.2010.10.008. Epub 2010 Oct 19.

17.
18.

Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice.

Tan AC, Mifsud EJ, Zeng W, Edenborough K, McVernon J, Brown LE, Jackson DC.

Mol Pharm. 2012 Sep 4;9(9):2710-8. doi: 10.1021/mp300257x. Epub 2012 Aug 3.

PMID:
22823162
19.

GM-CSF in the lung protects against lethal influenza infection.

Huang FF, Barnes PF, Feng Y, Donis R, Chroneos ZC, Idell S, Allen T, Perez DR, Whitsett JA, Dunussi-Joannopoulos K, Shams H.

Am J Respir Crit Care Med. 2011 Jul 15;184(2):259-68. doi: 10.1164/rccm.201012-2036OC. Epub 2011 Apr 7.

PMID:
21474645
20.

Innate immune control and regulation of influenza virus infections.

McGill J, Heusel JW, Legge KL.

J Leukoc Biol. 2009 Oct;86(4):803-12. doi: 10.1189/jlb.0509368. Epub 2009 Jul 30. Review.

Supplemental Content

Support Center